Report overview
This report contains market size and forecasts of MET Inhibitor Drugs in global, including the following market information:
Global MET Inhibitor Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global MET Inhibitor Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five MET Inhibitor Drugs companies in 2021 (%)
The global MET Inhibitor Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
C-Met Biological Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of MET Inhibitor Drugs include Abbott Laboratories, Johnson and Johnson, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co., Takeda Pharmaceutical Company, GlaxosmithKline plc, Amgen Inc. and Bristol Myers Squibb and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the MET Inhibitor Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global MET Inhibitor Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global MET Inhibitor Drugs Market Segment Percentages, by Type, 2021 (%)
C-Met Biological Inhibitors
Small Molecule C-Met Inhibitors
C-Met Antagonist Antibodies
HGF Antagonist Antibodies
Kringle Variant Antagonists
Global MET Inhibitor Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global MET Inhibitor Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Others
Global MET Inhibitor Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global MET Inhibitor Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies MET Inhibitor Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies MET Inhibitor Drugs revenues share in global market, 2021 (%)
Key companies MET Inhibitor Drugs sales in global market, 2017-2022 (Estimated), (K Units)
Key companies MET Inhibitor Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abbott Laboratories
Johnson and Johnson
Novartis International AG
Eli Lilly and Company
Pfizer Inc., Merck & Co.
Takeda Pharmaceutical Company
GlaxosmithKline plc
Amgen Inc.
Bristol Myers Squibb
Daiichi Sankyo Company, Limited
